By Kurt R. Nielsen, Ph.D., President and CEO, Pharmaceutics International, Inc (Pii)
The role of Chief Financial Officer for a small-to-mid size pharma company controlled by private equity is a challenging one. It requires balancing the competing demands of the Board of Directors, other executives, staff, and investors or shareholders.
However, most small-to-mid-size pharma companies with limited internal resources rely on CDMOs for support and they can be a great help to CFOs.
Kurt Nielsen, CEO of Pharmaceutics International shares his thoughts on how CFOs of pharma companies controlled by private equity can use their CDMOs to be more successful.